Drug intelligence / Profile preview

IBIO-201

Development stage: Preclinical
Lead developer: iBio
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

IBIO-201 is a subunit vaccine candidate for COVID-19 developed by iBio in collaboration with the Infectious Disease Research Institute (IDRI). The vaccine utilizes a SARS-CoV-2 spike protein antigen produced via iBio's plant-based FastPharming system, combined with the proprietary LicKM booster technology. LicKM (Lichenase-K-M) is a carrier protein designed to enhance the immune response to the antigen. The program was supported by IBM Watson Health's Clinical Development system to accelerate clinical trials and regulatory submissions. Preclinical studies were conducted to establish the vaccine's immunogenicity and manufacturing readiness.

Other names: iBio COVID-19 vaccine candidate

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on IBIO-201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IBIO-201.

Explore the full profile